Stoke Therapeutics Files 8-K
Ticker: STOK · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1623526
| Field | Detail |
|---|---|
| Company | Stoke Therapeutics, Inc. (STOK) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $175,000, $415,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Stoke Therapeutics filed an 8-K, likely containing routine updates or exhibit filings.
AI Summary
On September 10, 2024, Stoke Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company, incorporated in Delaware, is located at 45 Wiggins Avenue, Bedford, Massachusetts.
Why It Matters
This 8-K filing indicates that Stoke Therapeutics has submitted required documentation to the SEC, which may contain updates or disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events or financial disclosures that would indicate a change in risk.
Key Players & Entities
- Stoke Therapeutics, Inc. (company) — Registrant
- September 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 45 Wiggins Ave (address) — Principal Executive Offices
- Bedford, Massachusetts (location) — Principal Executive Offices
- 01730 (zip_code) — Principal Executive Offices
- 781-430-8200 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing for Stoke Therapeutics, Inc.?
The filing is a Current Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting 'Other Events' and 'Financial Statements and Exhibits'.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 10, 2024.
In which state is Stoke Therapeutics, Inc. incorporated?
Stoke Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Stoke Therapeutics, Inc.?
The principal executive offices are located at 45 Wiggins Ave, Bedford, Massachusetts, 01730.
Does the filing mention any former company names or addresses?
The filing notes 'Not Applicable' for former company name or former address, if changed since last report.
Filing Stats: 1,037 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-10 16:17:02
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo
- $175,000 — The Company subsequently agreed to pay $175,000 in attorneys' fees and expenses (the "M
- $415,000 — d of attorney's fees and expenses up to $415,000 to plaintiff's counsel. The Court must
Filing Documents
- d836605d8k.htm (8-K) — 29KB
- d836605dex991.htm (EX-99.1) — 65KB
- 0001193125-24-216632.txt ( ) — 234KB
- stok-20240910.xsd (EX-101.SCH) — 3KB
- stok-20240910_lab.xml (EX-101.LAB) — 18KB
- stok-20240910_pre.xml (EX-101.PRE) — 11KB
- d836605d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear, approved pursuant to a Scheduling Order dated August 27, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 10, 2024 STOKE THERAPEUTICS, INC. By: /s/ Thomas Leggett Thomas Leggett Chief Financial Officer